Bevacizumab in neoadjuvant treatment for breast cancer

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	1637; author reply 1638-40
Journal	The New England journal of medicine
Volume	366
Issue number	17
DOIs	https://doi.org/10.1056/NEJMc1202229
Publication status	Published - 26 Apr 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{a2eae1d67344424e995a074f2031aa66,

title = "Bevacizumab in neoadjuvant treatment for breast cancer",

author = "{van der Veldt}, {Astrid A M} and Smit, {Egbert F}",

year = "2012",

month = apr,

day = "26",

doi = "10.1056/NEJMc1202229",

language = "English",

volume = "366",

pages = "1637; author reply 1638--40",

journal = "The New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "17",

}

TY - JOUR

T1 - Bevacizumab in neoadjuvant treatment for breast cancer

AU - van der Veldt, Astrid A M

AU - Smit, Egbert F

PY - 2012/4/26

Y1 - 2012/4/26

U2 - 10.1056/NEJMc1202229

DO - 10.1056/NEJMc1202229

M3 - Comment/Letter to the editor

C2 - 22533581

SN - 0028-4793

VL - 366

SP - 1637; author reply 1638-40

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 17

ER -